Quintrio
Home

PHARMACEUTICAL PREPARATIONS

CryoPort, Inc. Common Stock

CYRX

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.

Last trade $19.91
Day change +$0.11 (+0.56%)
Day range $19.34 – $20.29
Volume 441,145
Market cap $1.00B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1B
Price / earnings
—
Price / book
2.07×
Price / sales
5.21×
EV / sales
4.74×
EV / EBITDA
-71.94×

Profitability

Earnings per share
-$0.97
Return on assets
-6.56%
Return on equity
-10.2%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.39×
Current ratio
2.04×
Quick ratio
1.94×
Cash ratio
1.25×

Cash flow

Price / cash flow
91.18×
Price / free cash flow
—
Free cash flow
-$18.81M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CYRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$50.22M$48.97M$47.8M$45.45M$44.23M$45.45M$41.04M$41.45M
Cost of revenue$26.39M$26.15M$25.89M$23.74M$22.91M$24.08M$22.4M$21.96M
Gross profit$23.83M$22.82M$21.91M$21.71M$21.33M$21.38M$18.64M$19.49M
Selling, general and administrative$27.9M$28.01M$27.62M$27.28M$26.73M$26.91M$21.9M$28.08M
Research and development$4.73M$4.85M$3.91M$4.47M$4.52M$4.12M$3.93M$4.16M
Total operating expenses$32.64M$32.86M$31.53M$31.74M$31.26M$31.03M$25.84M$32.24M
Operating income-$8.8M-$10.04M-$9.61M-$10.03M-$9.93M-$9.65M-$7.19M-$12.75M
Interest expense-$517K-$518K-$432K-$634K-$526K-$618K-$583K-$579K
Income before taxes-$10.66M-$7.75M-$9.32M-$7.4M-$6.53M-$11.74M-$6.5M-$17.31M
Income taxes$194K$505K$108K$1.13M$165K$274K$234K-$134K
Net income-$10.85M-$8.26M-$10.54M-$11.64M-$6.94M$108.87M-$11.98M-$18.68M
Net income attributable to common shareholders-$12.85M-$10.26M-$12.54M-$13.64M-$8.94M$106.87M-$13.98M-$20.68M
EBITDA-$2.34M-$3.45M-$3.21M-$3.68M-$3.52M-$2.35M$452K-$4.85M
Basic earnings per share-$0.25-$0.20-$0.25-$0.27-$0.18$2.13-$0.28-$0.42
Diluted earnings per share-$0.25-$0.20-$0.25-$0.27-$0.18$2.13-$0.28-$0.42

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates

CryoPort (CYRX) reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.19 loss by 31.58%. However, the company exceeded revenue expectations with $50.22 million versus the estimate of $48.68 million. The stock has gained 74% year-to-date but received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

Zacks Investment Research

Cencora (COR) Surpasses Q4 Earnings and Revenue Estimates

Cencora reported Q3 2026 earnings of $4.66 per share, beating consensus estimates of $4.56, with revenues of $88.35 billion slightly exceeding expectations. The company has outperformed consensus EPS estimates three times over the last four quarters. Despite underperforming the S&P 500 year-to-date, Cencora received a Zacks Rank #2 (Buy) rating with favorable estimate revision trends. The Medical Services industry ranks in the top 45% of Zacks industries.

Zacks Investment Research

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?

CryoPort, Inc. (CYRX) has returned 81.3% year-to-date, significantly outperforming the Medical sector's 1.6% average return. The company holds a Zacks Rank #2 (Buy) with improving earnings outlook. Delcath Systems, Inc. (DCTH) has also outperformed with a 58.1% year-to-date return and a Zacks Rank #1 (Strong Buy), supported by an 80.7% increase in consensus EPS estimates over three months.

Benzinga

Cryoport Reports First Quarter 2026 Financial Results

Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8 million, up 16% year-over-year, driven by strong performance in Life Sciences Services (18% growth) and Life Sciences Products (15% growth). Commercial CGT revenue grew 26% to $9.1 million, and the company supports a record 766 clinical trials and 21 approved therapies. The company raised full-year 2026 revenue guidance to $192-196 million and reported improved adjusted EBITDA from continuing operations.

GlobeNewswire Inc.

Biopharmaceutical Third Party Logistics (Distribution Management, Packaging & Labeling, Transportation, Warehousing) Market Research and Global Forecast Report 2026-2032

The biopharmaceutical third-party logistics market is expected to grow from $140.03 billion in 2025 to $384.23 billion by 2032, with a CAGR of 15.51%. Growth is driven by rising product complexity, regulatory scrutiny, cold chain integrity demands, and technological advancements in digital tracking and specialized handling for biologics and gene therapies.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 19, 20151-for-12reverse split
Feb 5, 20101-for-10reverse split
Mar 16, 20051.6-for-1forward split